Clinical trials: Follicular Thyroid Cancer
Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer
Studies on Tumors of the Thyroid
Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid…
- Conditions
- Hurthle Cell Thyroid Cancer, Tall Cell Variant Thyroid Cancer, Follicular Thyroid Cancer, Thyroid Cancer
- Trial name
- NCT00001160
- Testing
- 68-Gallium Dotatate
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm
Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial
This pilot clinical trial is intended to compare the effect of a psychosocial support tool for young adult (YA)cancer survivors - including high-quality information about their cancer combined with evidence-based psychosocial…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Malignant Testicular Neoplasm, Melanoma, Thyroid Gland Follicular Carcinoma
- Trial name
- NCT07529080
- Testing
- Internet-Based Intervention, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- University of Michigan Rogel Cancer Center
Differentiated Thyroid Carcinoma, Papillary Thyroid Carcinoma
Bethesda Classification and Risk Stratification in Differentiated Thyroid Carcinoma
This observational study aims to evaluate the relationship between preoperative Bethesda classification of fine-needle aspiration cytology and postoperative American Thyroid Association (ATA) risk stratification in patients with…
- Conditions
- Differentiated Thyroid Carcinoma, Papillary Thyroid Carcinoma, Follicular Thyroid Carcinoma
- Trial name
- NCT07858097
- Volunteers
- 100 people
- Sponsor
- Assiut University
Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer
This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT05575440
- Testing
- Computed Tomography, Fluorine F 18 Tetrafluoroborate, Positron Emission Tomography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Thyroid Cancer, Thyroid Cancer, Follicular
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
The purpose of this study is to find out whether a drug called PDR001, combined with either trametinib or dabrafenib, is a safe and effective treatment for thyroid cancer.
- Conditions
- Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer
- Trial name
- NCT04544111
- Testing
- Trametinib, Dabrafenib, PDR001
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body.
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma
- Trial name
- NCT02152995
- Testing
- Computed Tomography, Iodine I 124, Iodine I-131
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Gland Follicular Carcinoma
Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery
This study evaluates radioiodine planar and SPECT/CT imaging with iodine-123 in patients with follicular thyroid nodules prior to surgery.
- Trial name
- NCT05591092
- Testing
- Computed Tomography, Iodine I-123, Planar Imaging
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Papillary Thyroid Cancer, Hashimoto Disease
Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion
This study aim to assess for the incidence of thyroid cancer in patients with autoimmune thyroiditis (Inflammatory thyroid Lesions)
- Conditions
- Papillary Thyroid Cancer, Hashimoto Disease, Hashimoto's Thyroiditis, Follicular Thyroid Cancer
- Trial name
- Thyroid cancer (NCT07652450)
- Testing
- total thyroidectomy
- Where
- Egypt
- Volunteers
- 98 people
- Sponsor
- Minia University
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma
- Trial name
- NCT03914300
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors
This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid…
- Trial name
- NCT07545837
- Testing
- Counseling, Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby…
- Conditions
- Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma, Locally Advanced Thyroid Gland Oncocytic Carcinoma
- Trial name
- NCT06959641
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Jochen Lorch
Thyroid Cancer, Thyroid Neoplasms
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
- Trial name
- IoN (NCT01398085)
- Testing
- I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation
- Where
- 36 sites in United Kingdom
- Volunteers
- 504 people
- Sponsor
- University College, London
Thyroid Cancer, Thyroid Nodule
Surgical Competency for Robot-Assisted Thyroidectomy: Construction and Validation of a Robotic Thyroidectomy Assessment Score (RTAS)
To develop and validate a structured scoring tool (robotic thyroidectomy assessment score, RTAS) for assessing and quantifying surgical performance in robotic thyroidectomy (RT).
- Conditions
- Thyroid Cancer, Thyroid Nodule, Thyroid Diseases, Thyroid Cancer, Papillary
- Trial name
- NCT06730321
- Testing
- Observations on clinicopathological factors influencing the assessment score of surgery
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai 6th People's Hospital
Thyroid Cancer, Papillary Thyroid Cancer
Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer
Now, the investigators carried out a prospective study enrolling patients with thyroid cancer, who had received ablative thyroidectomy and /or radioactive iodine therapy for two more years.
- Conditions
- Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer
- Trial name
- NCT04948437
- Where
- Taiwan
- Volunteers
- 103 people
- Sponsor
- National Taiwan University Hospital
Thyroid Cancer, Follicular Thyroid Cancer
Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer
Thyroid cancer is the most common endocrine malignancy in the world. Generally, thyroid cancer could be divided into well-differentiated and poorly-differentiated.
- Trial name
- NCT05463107
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
This is a prospective, multi-centre, open label, stratified, exploratory phase II study evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with thyroid cancers.
- Conditions
- Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer
- Trial name
- DUTHY (NCT03753919)
- Testing
- Durvalumab, Tremelimumab
- Where
- 15 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT06440850
- Testing
- Biospecimen Collection, Cobimetinib, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Thyroid Carcinoma, Thyroid Cancer
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors.
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell)
- Trial name
- NCT04462471
- Testing
- I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery.
- Conditions
- Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma
- Trial name
- NCT02973997
- Testing
- Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Academic and Community Cancer Research United